A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma

A Dual Approach with Organoid and CRISPR Screening Reveals ERCC6 as a Determinant of Cisplatin Resistance in Osteosarcoma

Abstract Osteosarcoma (OS), the most prevalent primary bone malignancy in adolescents, is typically treated with cisplatin‐based chemotherapy. However, the development of cisplatin resistance often leads to relapse or metastasis, significantly impairing therapeutic efficacy. To tackle this issue, pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruiling Xu, Sai Zhu, Wenchao Zhang, Haodong Xu, Chao Tu, Honghui Wang, Lu Wang, Na He, Tang Liu, Xiaoning Guo, Xiaolei Ren, Zhihong Li
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Advanced Science
Subjects:
alternative splicing
chemoresistance
ERCC6
organoid
osteosarcoma
Online Access:https://doi.org/10.1002/advs.202500632
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202500632

Similar Items